Back to search results

EXCILYNT Study for Melanoma Lymph Node Metastasis

This study, called EXCILYNT, is looking at how effective it is to remove only the cancerous lymph node (a type of gland that is part of your immune system) in people with melanoma that has spread to one lymph node. Researchers want to see if this surgery prevents the cancer from coming back in the same area. They are also studying the side effects of the surgery and how it affects your quality of life. You could join if you have metastatic melanoma (cancer that has spread) to only one lymph node, detected by imaging or examination, and are a candidate for lymph node removal. The study will measure how many people have cancer return in the lymph node area after 3 years.

Study design
This interventional study plans to enroll 66 participants. It compares two surgical approaches for removing a cancerous lymph node.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 3 years after their lymph node excision to measure recurrence.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05839912

Excision of Lymph Node Trial (EXCILYNT) (Mel69)

Recruiting
NAAges 18+InterventionalTreatment
Craig L Slingluff, Jr
~66 participants
Updated 2025-09-17 on ClinicalTrials.gov
What's tested:Excision of clinically detected lymph node metastasis before any systemic therapyExcision of clinically detected lymph node metastasis after neoadjuvant systemic therapy

At a glance

Recruiting sites
5 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Node basin-only recurrence
Measured over 3 years after the lymph node excision

Conditions

Melanoma

Explore related trials

Melanoma

Where it's being run

7 sites across 7 states
Georgia1
Maryland1
Michigan1
New York1
North Carolina1
Pennsylvania1
Virginia1

Study leadership

  • Craig L Slingluff, Jr., MD · PRINCIPAL_INVESTIGATOR · University of Virginia

Who to contact

Samantha Schaeffer
[email protected]
434-982-6714
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

PET-CT scan, and
Head CT scan or MRI These scans may have been performed prior to resection of the primary melanoma and/or sentinel node biopsy if they showed no evidence of other metastases.

What this trial measures

  • Node basin-only recurrence3 years after the lymph node excision

    Number of participants with recurrence of melanoma within the node basin without concurrent or preceding distant metastatic recurrence